Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity.

NCT03017729 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT03017729
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03017729 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity.
Lead sponsor
Ipsen
Phase
Observational
Overall status
Completed
Start date
February 10, 2017
Completion date
November 30, 2020
Enrollment
242 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

lower limb spasticity